R. Moodliar
Research Subjects
Research Interests
R. Moodliar has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
C. Kambili
Johnson & Johnson Global Public Health, New Brunswick, NJ, USA
1 shared publicationE. Birmingham
Janssen Research & Development, Raritan, NJ
1 shared publicationG. Mao
Janssen Research & Development, Titusville, NJ
1 shared publicationJ. van de Logt
Janssen Research & Development, Leiden, The Netherlands
1 shared publicationM. V. G. Frias
De La Salle Health Sciences Institute, Dasmariñas City, Cavite, the Philippines
1 shared publicationN. Bakare
Janssen Research & Development, Titusville, NJ
1 shared publication
Latest Publications
- Open Access
- 1 September 2021
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 25 (9) , 716-724
Bedaquiline for multidrug-resistant TB in paediatric patients
BACKGROUND: TMC207-C211 (NCT02354014) is a Phase 2, open-label, multicentre, single-arm study to evaluate pharmacokinetics, safety/tolerability, antimycobacterial activity and dose selection of bedaquiline (BDQ) in children (birth to METHODS: Patients received 24 weeks’ BDQ with an anti-MDR-TB background regimen (BR), followed by 96 weeks of safety follow-up. Results of the primary analysis are presented based on data up to 24 weeks for Cohort 1 (≥12–CONCLUSION: In children and adolescents aged ≥5–<18 years with MDR-TB, including pre-extensively drug-resistant-TB (pre-XDR-TB) or XDR-TB, 24 weeks of BDQ provided a comparable pharmacokinetic and safety profile to adults.
- 1 September 2021
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 25 (9) , 716-724
Open AccessBedaquiline for multidrug-resistant TB in paediatric patients
BACKGROUND: TMC207-C211 (NCT02354014) is a Phase 2, open-label, multicentre, single-arm study to evaluate pharmacokinetics, safety/tolerability, antimycobacterial activity and dose selection of bedaquiline (BDQ) in children (birth to METHODS: Patients received 24 weeks’ BDQ with an anti-MDR-TB background regimen (BR), followed by 96 weeks of safety follow-up. Results of the primary analysis are presented based on data up to 24 weeks for Cohort 1 (≥12–CONCLUSION: In children and adolescents aged ≥5–<18 years with MDR-TB, including pre-extensively drug-resistant-TB (pre-XDR-TB) or XDR-TB, 24 weeks of BDQ provided a comparable pharmacokinetic and safety profile to adults.